An Exploratory, Multicenter, Observational Study to Examine RNA Biomarkers of Psoriasis Subjects Through the Application of the Mindera Kit Part 2 (STAMP-2).

Mindera Health0 sites100 target enrollmentAugust 1, 2021

ConditionsPsoriasis

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Psoriasis
Sponsor: Mindera Health
Enrollment: 100
Primary Endpoint: Observation of on therapy transcriptomics to potentially aid in new therapeutic targets
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

A 16 week study to examine if baseline or on-therapy transcriptomics can be used to help predict selection of medications and provide new therapeutic targets for drug development in psoriasis subjects.

Registry

clinicaltrials.gov

Start Date

August 1, 2021

End Date

May 30, 2022

Last Updated

4 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Mindera Health

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Outcomes

Primary Outcomes

Observation of on therapy transcriptomics to potentially aid in new therapeutic targets

Time Frame: 16 weeks

To examine if baseline or on-therapy transcriptomics can be used to help predict selection of medications and provide new therapeutic targets for drug development in psoriasis subjects by collecting RNA and examining changes in PASI scores at the Week 4, 12, and 16 timepoints.